Using cord blood eye drops to heal corneal damage in lung cancer patients
Personalized Approach in the Treatment of Patients Affected by Severe Dry Eye Associated With Therapy With EGFR Inhibitors (EGRFR-I) With Growth Factors in Cord Blood Serum (CBS) Eye Drops
This study is testing if eye drops made from cord blood can help lung cancer patients with EGFR mutations heal their eye damage caused by treatment.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 10 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | IRCCS Azienda Ospedaliero-Universitaria di Bologna Academic / other |
| Locations | 1 site (Bologna) |
| Trial ID | NCT06830551 on ClinicalTrials.gov |
What this trial studies
This study evaluates the effectiveness of cord blood serum eye drops in promoting the healing of corneal epithelium in patients receiving EGFR inhibitor treatment for lung cancer. The intervention involves administering these eye drops over a one-month period to assess their impact on corneal damage caused by the medication. The study focuses on oncology patients with EGFR mutations who are experiencing severe keratopathy as a side effect of their treatment.
Who should consider this trial
Good fit: Ideal candidates are adults over 18 years old with advanced cancer and EGFR mutations requiring anti-EGFR treatment.
Not a fit: Patients unable to independently store or administer the eye drops will not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could significantly improve the quality of life for patients suffering from corneal damage due to cancer therapies.
How similar studies have performed: While the use of cord blood serum in ocular treatments is promising, this specific approach is novel and has not been extensively tested in similar studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * age over 18 years * oncology and advanced cancer patients who have EGFr mutation and who require treatment with antiEGFr drugs * signing of informed consent Exclusion Criteria: * Patients who are unable to store/administer the CSCO independently, or with the help of care-givers.
Where this trial is running
Bologna
- IRCCS Azienda Ospedaliero-Universitaria di Bologna — Bologna, Italy (Recruiting)
Study contacts
- Principal investigator: Luigi Fontana, MD — IRCCS Azienda Ospedaliero-Universitaria di Bologna
- Study coordinator: Luigi Fontana, MD
- Email: luigi.fontana6@unibo.it
- Phone: +390512142837
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.